The preventive effects of two nutraceuticals on experimentally induced acute synovitis by Van de Water, Eline et al.
The preventive effects of two nutraceuticals on experimentally
induced acute synovitis
E. VAN DE WATER†*, M. OOSTERLINCK†, M. DUMOULIN†, N. M. KORTHAGEN‡, P. R. VAN WEEREN‡,
J. VAN DEN BROEK§, H. EVERTS§, F. PILLE†1 and D. A. VAN DOORN‡§¶1
†Department of Surgery and Anaesthesiology, Faculty of Veterinary Medicine, Ghent University, Belgium
‡Department of Equine Sciences, Faculty of Veterinary Medicine, Utrecht University, The Netherlands
§Department of Farm Animal Health, Faculty of Veterinary Medicine, Utrecht University, The Netherlands
¶Equivado, Equine Nutrition Consultancy, Utrecht, The Netherlands.
*Correspondence email: eline.vandewater@ugent.be; Received: 16.02.16; Accepted: 19.08.16
1These authors contributed equally to this work.
Summary
Background: Nutraceuticals are often used in the management of equine osteoarthritis, but scientific evidence of their efficacy is lacking.
Objectives: To study the preventive effects of two new nutraceuticals after the experimental induction of synovitis in comparison with positive and
negative control treatments.
Study design: Blinded, controlled, randomised experiment.
Methods: Twenty-four healthy Standardbred horses were randomly allocated to supplement AT (multi-ingredient, 28 days), supplement HP (collagen
hydrolysate, 60 days), meloxicam (4 days) or placebo (60 days). Synovitis was induced in the right intercarpal joint by intra-articular injection of 0.5 ng
lipopolysaccharide (LPS) of Escherichia coli while treatments were continued. Blood and synovial fluid were sampled before treatment, immediately
prior to LPS injection, and at 8, 24 and 48 h post-injection. Synovial fluid samples were analysed for total nucleated cell count (TNCC), total protein (TP)
and selected biomarkers (prostaglandin E2 [PGE2], interleukin-6 [IL-6], glycosaminoglycans [GAGs], type II collagen synthesis [CPII], matrix
metalloproteinase [MMP]). Lameness was scored by visual examination and pressure plate analysis immediately prior to LPS injection, and at 8, 24 and
48 h post-injection. Clinical examinations were performed before treatment, immediately prior to LPS injection, at 2, 4 and 6 h post-injection, and then
twice per day during the test period.
Results: Before treatment and intra-articular challenge, there were no statistically significant differences among the treatment groups for any of the
parameters. After intra-articular challenge, the placebo group showed significantly higher synovial fluid TP, TNCC and PGE2 compared with the
meloxicam group, although the model did not induce a relevant amount of lameness. Both nutraceuticals resulted in significantly lower synovial fluid
TP, TNCC and PGE2 compared with placebo. No statistical differences in IL-6, GAGs, CPII or MMPs were observed among treatment groups. No adverse
effects were observed.
Main limitations: Despite evidence of synovitis, lameness was too mild to detect.
Conclusions: The preventive administration of these nutraceuticals showed anti-inflammatory effects in this validated synovitis model. Therefore,
further studies of their clinical applicability are warranted.
The Summary is available in Chinese – see Supporting information.
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Introduction
Nutraceuticals are often used in the management of osteoarthritis, which is
a common cause of chronic lameness in horses [1]. However, their
‘curative’ efficacy remains controversial [2,3] and the quality of relevant
studies is generally low [4,5]. Equine in vitro studies have suggested that
the combination of glucosamine and chondroitin sulphate can result in
reduced cartilage degradation [6–8] and may have anti-inflammatory
effects [6,9,10]. Although their oral bioavailability in horses is reported to
be low [11,12], an in vivo study in osteoarthritic horses showed significant
clinical improvement after treatment with glucosamine and chondroitin
sulphate compared with placebo treatment [13]. Furthermore,
methylsulphonylmethane (MSM) is a natural anti-inflammatory agent [14]
that has been found to decrease joint pain and swelling in human subjects
with osteoarthritis [15,16] and to significantly ameliorate exercise-related
oxidative and inflammatory blood changes in jumping horses [17]. Finally,
collagen hydrolysate showed a stimulatory effect on type II collagen
biosynthesis of chondrocytes in an in vitro model with bovine
chondrocytes [18]. Moreover, several studies showed beneficial effects of
collagen hydrolysate on joint pain associated with osteoarthritis in human
subjects [19,20]. Studies of its efficacy in equine cases are lacking, but it
has been found to be well absorbed and available for amino acid
metabolism in horses [21].
Until now, the aforementioned nutraceuticals have only been tested
using in vitro studies or in selected patients from a curative perspective.
As inflammation plays a crucial role in the pathogenesis of osteoarthritis,
reducing the initial inflammation can be seen as the cornerstone of
preventive treatment. The efficacy of prevention can be studied using a
validated synovitis model based on the intra-articular injection of
lipopolysaccharide (LPS) [22,23]. Therefore, a blinded, controlled,
randomised study was designed to test the effects of two nutraceuticals
using the validated model of acute synovitis described above and a
comprehensive set of objective synovial and clinical variables as
outcome parameters. These included quantitative locomotion analysis
using a pressure plate and an array of synovial biomarkers. The
hypothesis was that preventive administration of these nutraceuticals
would have a beneficial effect on the degree of joint inflammation and
lameness.
This is an open access article under the terms of the Creative Commons Attribution
License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
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Materials and methods
Study design
The study was a blinded, controlled, randomised experiment in a block
design with four treatment groups of six horses per group, all housed
under the same conditions. Horses were randomly allocated to one of four
dietary treatments: 1) supplement ‘AT’ (Cavalor ArtiTec [Liquid]a, containing
glucosamine sulphate 2KCL, shark chondroitin sulphate sodium, MSM,
boswellic acid dry extract 65%, Ananasus comosus extract 2500 GDU, L-
glutamine, feverfew dry extract PE 4:1, hyaluronic acid), administered at
45 mL twice per day for 28 days prior to articular challenge and during the
3-day test period; 2) supplement ‘HP’ (Hydro-Pb, collagen hydrolysate), at
90 g once per day for 60 days prior to articular challenge and during the 3-
day test period; 3) meloxicam (Metacamc), at 0.6 mg/kg once per day for
4 days prior to articular challenge and during the 3-day test period
(positive control); and 4) placebo (casein), at 90 g once per day for 60 days
prior to articular challenge and during the 3-day test period (negative
control).
The number of horses (n = 6) per treatment group was statistically
determined using an a priori power analysis test [24] for the primary
outcome variable (prostaglandin E2 [PGE2]), based on the published
standard error of PGE2 concentration in synovial fluid in horses with
synovitis [22], and a mean estimated effect of a nutraceutical treatment of
45% PGE2 reduction [25], at a = 0.05; b = 0.2, and an effect size of 1.68.
Experimental procedures started 61 days before the articular challenges
(post-injection day [PID] 61), when blood and synovial fluid samples were
obtained to provide baseline data before supplementation. Immediately
prior to the articular challenge with LPS of Escherichia coli (PID 0), blood
and synovial fluid were sampled and gait evaluation (visually and by
pressure plate analysis) was performed to establish baseline values before
the induction of arthritis. The latter procedures were repeated at 8 h (PID
0.3), 24 h (PID 1) and 48 h (PID 2) post-injection (Fig 1). Horses were
blocked in groups of four based on body weight and age. Treatments were
randomly allocated within each block and blocks were entered into the
study at 1-week intervals.
Horses
The study included 24 healthy and clinically sound female French (n = 19),
Belgian (n = 4) and Dutch (n = 1) Standardbred horses (mean  s.d. age:
9  2.8 years; mean  s.d. body weight: 495.9  38.9 kg), obtained
from a local breeding centre. Horses with a known history of lameness or
gastrointestinal problems were excluded from the study.
Feeding and supplementation
Horses were individually fed a standardised diet of concentrates and high-
quality hay that met their nutritional requirements [26]. Horses subjected to
treatment AT, meloxicam and placebo received the placebo supplement,
and horses subjected to treatment HP received the HP supplement, top-
dressed over the morning concentrate ration. The morning dose AT and
meloxicam were administered orally prior to the morning concentrate feed
ration.
Intra-articular challenge
At PID 0, after baseline pressure plate analysis and arthrocentesis,
synovitis was induced in the right intercarpal joint by injection of 0.5 ng
LPS from E. coli (L5418d) (lot 093M4041V) in 0.8 ml sterile isotonic saline
[22]. Two weeks prior to the start of the study, the initial LPS solution
(1 mg/ml) was aseptically diluted to a final concentration of 0.625 ng/ml.
The diluted LPS solutions were stored in glass vials at 4°C.
Physical examination (respiratory rate, heart rate and rectal temperature)
was performed immediately prior to LPS injection, at 2, 4 and 6 h after LPS
injection, and then twice per day during the test period to control for
systemic signs of endotoxaemia.
Sampling
Synovial samples were taken at PID 61, PID 0, PID 0.3, PID 1 and
PID 2. If necessary, horses were sedated with detomidine 10 lg/kg and
butorphanol 10 lg/kg i.v. Prior to arthrocentesis, the right intercarpal
joint region was clipped and aseptically prepared. With a flexed carpus,
a 21 gauge, 4-cm needle was inserted between the extensor carpi
radialis and common digital extensor tendons [27]. Approximately
3.5 mL of synovial fluid was withdrawn and immediately split into
different sterile containers: 1 mL was collected in an EDTA-coated tube
and the remaining amount of fluid was collected in plain tubes.
Samples were immediately stored at 4°C and analysed (EDTA) or
processed (plain tubes) within 1 h of collection. The EDTA aliquot was
analysed for cytology (total nucleated cell count [TNCC]) and total
protein ([TP]). The aliquot in plain tubes was centrifuged at 600 g for
20 min, aliquoted and stored at 80°C within 2 h after collection for
subsequent biomarker analysis.
Blood samples were taken from the left jugular vein with a 21 gauge, 4-
cm needle and put in silicone-coated and EDTA-coated vacutainers.
Samples were immediately refrigerated (4°C), and subsequently transferred
to the laboratory for further analysis. PID 0 samples were analysed for
haematology and serum biochemistry and compared with PID 61
samples to assess treatment safety. The serum biochemistry panel
included urea, creatinine, TP, albumin, a-globulins, b-globulins, c-globulins,
total bilirubin, direct and indirect bilirubin, aspartate aminotransferase,
c-glutamyltransferase (GGT), alkaline phosphatase, lactate dehydrogenase
and creatine kinase. At PID 0.3, PID 1 and PID 2 only haematology was
performed to assess LPS safety.
Synovial biomarker analysis
Prostaglandins were determined by high-performance liquid
chromatography (HPLC)–tandem mass spectrometry (MS/MS) analysis
following RP-18 extraction of synovial fluid samples [28]. HPLC-MS/MS
analysis was performed on a PerkinElmer LC200 HPLC systeme coupled to
an electrospray ionisation linear ion trap quadrupole (4000 QTRAP) mass
spectrometerf. The instrument was operated in negative MRM mode. PGE2
concentrations were calculated from peak areas relative to an internal
standard.
Synovial fluid samples were evaluated for glycosaminoglycan (GAG)
content using the 1,9-dimethylmethyleneblue assay, adapted for use in
microtitre plates [28].
Interleukin-6 (IL-6) was measured using the GSI Equine IL-6 ELISA Kitg for
synovial fluid, in which undiluted synovial samples were found to give the
best results.
CPII, a marker of type II collagen synthesis, was quantified using
commercial ELISA kitsh, as described in other studies [27,29,30], in
accordance with the manufacturer’s recommendations.
General matrix metalloproteinase (MMP) activity was measured using the
fluorogenic substrate FS-6i. In short, samples were diluted 20-fold in MMP
buffer (0.1 mol/l Tris, 0.1 mol/l NaCl, 10 mmol/l CaCl2, 0.05% [w/v] Triton
X-100, 0.1% [w/v] PEG6000, pH 7.5 and 5 lmol/l FS-6). Samples were added
in triplicate to a black 384-well microplatej and the fluorescent signal was
monitored continuously for 45 min at 37°C using a CLARIOstar microplate
readerk. The slope of the resultant linear curve (relative fluorescence units/s
[RFU/s]) was calculated as a measure of general MMP activity. A quantity of
5 mmol/l EDTA was used as a negative control.
Clinical evaluation
Lameness was scored prior to arthrocentesis. At PID 61, this was
performed by routine visual examination only using the American
Start HP
Start placebo
Day
PID –61 PID 0 PID 1
PID 2PID 0.3
Treatment period
0 ... ... ... ... ... ... ...33 57 58 59 60 61 62 63 64
Start AT Start meloxicam LPS injection
Fig 1: Timeline of treatments (HP, supplement HP; AT, supplement AT; LPS,
lipopolysaccharide) and evaluation points, displayed by post-injection day (PID).
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Association of Equine Practitioners (AAEP) scale, on which grade 0
represents sound ability and grade 5 indicates non weight bearing
capacity, by two European College of Veterinary Surgeons diplomates,
using video-recordings [31]. At PID 0, PID 0.3, PID 1 and PID 2, both video-
recordings and pressure plate measurements were used.
Pressure plate measurements were obtained using a Footscan 3D
2m-systeml as described by Oosterlinck et al. [32]. The following kinetic
variables were calculated at walk and trot: 1) peak vertical force (PVF), in N/
kg; 2) vertical impulse (VI), in Ns/kg; and 3) stance time (ST) in ms. For each
set of five trials, all left forelimb (LF) and right forelimb (RF) measurements
were averaged and subsequently PVF, VI and ST ratios between both
forelimbs were calculated as: %RF = RF/(LF + RF) 9 100%.
Data analysis
Statistical analysis was performed using R (lme4 package)m. A linear model
with random horse effects and with fixed week, time, sedation, treatment
and the time–treatment interaction was used. Akaike’s information
criterion (AIC) was used for model reduction [33]. Week and sedation were
considered as block factors. If a factor was important according to the AIC,
then 90% bootstrap intervals were calculated for the effect. Residuals were
checked for normality using a normal probability plot. TNCC, PGE2, CPII and
MMP data were logarithmically transformed for statistical analysis. Clinical
lameness scores required a logistic regression, but with exactly the same
model as described above.
Results
Synovial fluid analysis
The results of synovial fluid analysis are presented in Table 1. At PID 61
and PID 0, there were no statistical differences among treatment groups.
After LPS injection, there was a marked increase in TNCC in all treatment
groups, with a sharp peak at PID 0.3 (Fig 2a). At all time points after LPS
TABLE 1: Results of synovial fluid analyses of total nucleated cell count (TNCC), total protein (TP), prostaglandin E2 (PGE2), interleukin-6
(IL-6), glycosaminoglycans (GAGs), matrix metalloproteinases (MMPs) and type II collagen synthesis (CPII) taken at post-injection days
(PIDs) 61, 0, 0.3, 1 and 2, in the four treatment groups (meloxicam [Melox], supplements AT and HP, and placebo [Plac])
PID 61 PID 0 PID 0.3 PID 1 PID 2
TNCC, 9109/L
median (range)
Melox 0.17 (0.12–0.41) 0.11 (0.05–0.15) 61.31 (42.93–78.15)a 21.89 (9.05–60.55)a 3.59 (1.52–8.43)a
AT 0.21 (0.12–0.35) 0.16 (0.10–0.29) 45.70 (31.75–61.75)a 15.00 (7.88–26.41)a 4.59 (1.21–8.16)a
HP 0.15 (0.09–0.31) 0.20 (0.08–0.41) 55.36 (14.52–103.40)a 17.90 (2.83–26.60)a 4.95 (1.16–6.67)a
Plac 0.23 (0.15–0.33) 0.15 (0.11–0.21) 80.67 (68.81–113.37)b 26.54 (12.78–80.35)b 6.89 (2.55–8.89)b
TP, g/L
mean  s.d.
Melox 15.70  3.88 16.33  4.46 31.33  7.23a 36.33  5.85a 21.33  1.63a
AT 15.50  3.33 18.33  1.97 37.67  8.62a 40.67  4.13a 24.33  3.88a,b
HP 16.70  1.97 17.67  3.67 37.33  10.17a 40.67  8.64a 25.33  3.50a,b
Plac 14.20  3.37 18.67  6.53 50.33  3.20b 48.00  8.10b 29.00  4.15b
PGE2, pg/ml
median (range)
Melox 27.28 (9.92–143.78) 16.09 (9.02–23.10) 53.22 (19.05–127.70)a 33.05 (20.69–79.50)a 30.65 (15.45–58.01)a
AT 29.42 (9.95–107.28) 28.20 (8.78–99.44) 795.06 (415.43–1571.29)b 119.72 (96.75–308.46)b 130.50 (83.32–264.85)b,c
HP 36.04 (12.42–91.52) 30.14 (13.83–70.14) 2307.82 (234.25–12,517.59)c 268.88 (153.72–439.99)b,c 154.79 (72.01–443.62)b,c
Plac 36.41 (25.21–157.01) 14.98 (9.10–203.64) 3795.08 (720.28–40,960.19)d 304.56 (101.90–3524.93)c 268.31 (133.20–820.07)c
IL-6, pg/ml
mean  s.d.
Melox 3.35  8.21 3.79  6.10 29.69  29.82 32.82  44.09 15.16  18.94
AT 14.56  30.10 48.40  106.65 126.5  261.29 118.72  255.30 81.37  188.09
HP 6.85  15.29 8.04  19.70 54.92  81.79 48.40  91.77 25.62  44.61
Plac 5.15  12.62 9.40  19.72 46.69  60.54 29.24  37.01 12.15  13.93
GAGs, lg/ml
mean  s.d.
Melox 114.50  42.86 108.20  36.03 180.71  26.99 245.61  78.46 158.17  49.77
AT 106.80  19.78 114.22  13.47 178.13  24.28 241.02  33.56 178.91  25.94
HP 112.50  29.90 115.70  28.30 177.34  39.77 247.95  88.03 205.00  71.36
Plac 125.10  18.82 126.53  17.10 191.41  22.94 291.59  78.04 230.05  67.30
MMPs, RFU/s
median (range)
Melox 251.73 (157.20–451.47) 215.20 (95.67–396.80) 276.33 (157.20–568.00) 692.70 (295.40–1108.40) 418.13 (239.00–574.27)
AT 232.23 (83.20–465.40) 217.72 (152.40–317.80) 695.37 (343.67–1050.60) 929.63 (521.20–1475.87) 511.47 (270.87–703.87)
HP 244.13 (118.47–489.13) 222.77 (95.13–365.73) 493.93 (126.13–712.07) 861.80 (466.13–1300.53) 556.47 (224.67–650.33)
Plac 285.40 (115.20–440.00) 211.20 (72.80–334.20) 388.93 (33.67–967.67) 908.07 (726.73–1328.13) 592.83 (524.33–700.33)
CPII, ng/ml
median (range)
Melox 1035.91 (264.40–8681.40) 678.86 (521.07–1538.08) 1388.69 (969.47–1662.18) 1732.70 (1085.27–2535.43) 2117.65 (910.16–4948.36)
AT 1054.89 (538.99–1569.74) 1031.74 (341.15–1207.49) 1186.43 (253.31–2560.36) 3631.69 (866.49–6320.83) 4379.43 (828.20–6203.69)
HP 660.33 (373.05–1075.67) 869.76 (290.59–1094.46) 1058.04 (323.97–2289.94) 6103.99 (1032.04–8639.12) 4283.48 (1278.48–12,303.01)
Plac 436.35 (38.12–609.66) 814.47 (33.50–1883.84) 1181.77 (635.77–2874.65) 3583.98 (1117.20–12,341.05) 7653.97 (1591.68–23,051.08)
RFU/s, relative fluorescence units/s. Within time points, treatments with different superscripts show statistically significant differences.
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injection, meloxicam treatment and both supplement treatments resulted
in a statistically lower TNCC than placebo treatment. There were no
statistically significant differences between the meloxicam group and both
supplement groups.
Total protein showed a sustained increase in all treatment groups at
PID 0.3 and PID 1 (Fig 2b). At PID 0.3 and PID 1, TP in the meloxicam
group and both supplement groups was statistically lower than in the
placebo group. At PID 2, TP in the meloxicam group only was statistically
lower than in the placebo group.
Over time, the concentration of PGE2 showed a rise at PID 0.3 (Fig 3).
IL-6 and GAGs showed more sustained rises at PID 0.3 and PID 1, and
MMPs and CPII peaked at PID 2. The PGE2 concentration was statistically
lower in the meloxicam group than in the other treatment groups at
PID 0.3. Supplement AT resulted in statistically lower PGE2 concentrations
than supplement HP and placebo treatment, and supplement HP resulted
in statistically lower PGE2 concentrations than placebo treatment at this
time point. At PID 1, PGE2 was statistically lower in the meloxicam group
than in all other treatment groups. Moreover, supplement AT resulted in
statistically lower PGE2 concentrations than placebo treatment at this time
point, by contrast with supplement HP. However, there was no statistically
significant difference between the two supplement groups at this time
point. At PID 2, PGE2 was statistically lower in the meloxicam group than in
all other treatment groups. IL-6, GAG, CPII and MMP concentrations
showed no statistically significant differences between treatment groups at
any time point.
Lameness evaluation
Lameness was very mild (AAEP score ≤1) and visually detectable only at
PID 0.3 in some horses (four of 24) and at PID 1 in one horse. Clinical
lameness scores did not differ statistically between treatment groups. Even
with pressure plate analysis, no statistical differences in PVF and VI left-to-
right ratios between treatment groups could be observed at any time
point. For ST, very small and inconsistent differences between treatment
groups could be observed at trot after LPS injection.
Safety of supplements and LPS injection
After supplementation (at PID 0), serum activity of GGT was increased in 21
of 24 (88%) horses (mean  s.d.: 101.6  61.9 U/L; reference range:
0–30 U/L) across all four groups, including the placebo group, and hence
without any association with treatment. Other blood parameters
(haematology and serum biochemistry) were within normal limits. After LPS
injection, blood haematology and routine clinical examinations revealed no
systemic abnormalities at any time point.
Discussion
In vivo equine studies on nutraceuticals are usually clinical trials [13,34,35],
which are subject to an inherent lack of standardisation. This is highlighted
by the low-quality appraisal of most nutraceutical studies, using the score
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list described by Pearson and Lindinger [4]. To overcome the limitations of
clinical studies, experimental models can be used as these provide highly
standardised circumstances. Using an IL-1b-based experimental synovitis
model, Pearson et al. [25] studied the effect of a nutraceutical (composed
of mussel, shark cartilage, abalone and Biota orientalis lipid extract) on the
inflammatory response in synovial fluid. In a subsequent study of another
nutraceutical (a biological extract of high-rosmarinic acid mint) [36],
synovitis was induced by injection of LPS and, in addition to synovial fluid
analysis, lameness was assessed as an outcome parameter, albeit
subjectively. The current study is the first to show an anti-inflammatory
effect of nutraceuticals on experimentally induced synovitis using a
comprehensive set of objective synovial and clinical variables, including
analysis of inflammatory and cartilage biomarkers, and quantitative
evaluation of locomotion, which results in an excellent quality score (>80.0)
according to the classification by Pearson and Lindinger [4].
In the current study, clear synovial inflammation was observed after
LPS injection, especially in the placebo group. Moreover, the registered
non-steroidal anti-inflammatory drug meloxicam resulted in significant
reductions in TNCC, TP and PGE2 concentrations compared with the
placebo treatment, indirectly confirming the validity of the synovitis model
used in this study. The resulting lameness, however, was too mild to be
detectable, either visually or by pressure plate evaluation, and therefore
could not be used as a parameter with which to discriminate between
treatments. This contrasts with the findings of de Grauw et al. [22], who
found a mean lameness score of 3/5 on the AAEP grading scale for the
placebo treatment at 8 h post-injection with the same LPS dose. This
discrepancy is most likely attributable to differences in LPS activity
between lots, but may also relate to the use of different handling
procedures to create the diluted LPS solution, the use of Standardbred
horses in the present study vs. Warmbloods in the study conducted by
de Grauw et al. [22], or a combination of these factors. Breed-dependent
effects may be suspected. Pearson et al. [36] reported that no more than
three of eight Standardbred horses showed grade 1 lameness on the
AAEP scale 12 h after LPS injection in the intercarpal joint and that none
of them showed any lameness at 24 h, although they used a slightly
lower dose (0.3 ng LPS of E. coli O55:B5). Positive aspects of this issue
are that horses suffered less, which is good from an equine welfare
perspective, and that the subtle lameness induced resembles the clinical
situation in osteoarthritis to a greater degree than the more fulminant
inflammatory reaction described by de Grauw et al. [22]. Nevertheless, a
slightly higher degree of lameness would have permitted quantitative gait
analysis.
The less pronounced lameness in the present study in comparison with
that reported by de Grauw et al. [22] was mirrored by a lower peak TNCC
and lower maximal CPII concentration than described in the earlier paper
and reflects a slightly lower degree of inflammation. However, the
effectiveness of the experimental model is illustrated by the statistically
relevant increases in cell counts and inflammatory biomarkers in the
placebo group and the statistically significant differences between the
meloxicam and placebo treatments for TNCC and TP. The maximal
concentrations of PGE2 and GAG were similar to those described by de
Grauw et al. [22], but by contrast with the study conducted by de Grauw
et al. [23], the present study did not reveal a statistically significant
difference in GAG content between the meloxicam and placebo
treatments.
The statistically lower TNCC, TP and PGE2 concentrations after LPS
injection in both supplement groups compared with the placebo treatment
group prove that both supplements have anti-inflammatory effects. As
inflammation plays an important role in the pathogenesis of osteoarthritis
[37,38], it is plausible that these supplements may be of benefit during the
developmental stage of osteoarthritis. Unfortunately, the acute, temporary
synovitis model does not allow for the drawing of conclusions about
possible long-term effects.
Apart from an increase in serum GGT activity, no changes in blood
haematology or serum biochemistry were observed after supplementation.
Increased GGT activity was observed in all treatment groups, including the
placebo group, which suggests it was not associated with the
supplementation; therefore, the present authors conclude that the periods
of supplementation with the products described here (28 days for AT and
60 days for HP) can be considered safe. The reason for the increased GGT
activity in all groups remains unclear. The horses did not show any clinical
symptoms of liver disease or any other abnormalities. There was no
dietary change during the study.
The limitations of the current study are that the clinical evaluation of
horses’ locomotion was based on video-recordings, and that pressure
plate analysis was not performed prior to articular challenge. There are
inherent limitations in the evaluation of locomotion using video-recordings
compared with a full clinical examination, but the use of video-recordings
avoided observer bias at individual time points. Moreover, pressure plate
analysis confirmed the absence of relevant asymmetry in horses’
locomotion. At PID 61, measurements were performed at a breeding
farm at which a large herd of horses was available, whereas the induction
of synovitis and pressure plate analysis were performed at the university
hospital. Pressure plate equipment was not available at the breeding farm.
However, the aim of the study was not to compare locomotion before and
after supplementation with nutraceuticals, but to evaluate the effects of
the preventive administration of nutraceuticals on the acute synovitis
induced with LPS.
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Fig 3: Logarithmically transformed mean prostaglandin E2 (PGE2) concentrations in synovial fluid in the different treatment groups (green: meloxicam; blue: supplement
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show statistically significant differences.
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Conclusions
The nutraceuticals investigated in this study ameliorated experimental joint
inflammation in a validated synovitis model. Therefore, the clinical benefits
of these products in patients with various degrees of joint pathology
should be evaluated.
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